GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2
2024-05-31
细胞疗法临床2期免疫疗法
SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients.
The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors. Quanqi (125SER), as a domestically marketed human Interleukin-2, is primarily used in the treatment of solid tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer, etc. Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients.
Grit is a clinical stage cell therapy company leading the tumor infiltrating lymphocytes (TILs) therapy development in China. Grit's non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial -- it is the fastest TIL pipeline in China and plans for BLA filing in 2025. Quangang Pharmaceutical is a leading domestic biopharmaceutical company dedicated to the research and development of genetic medicines, boasting GMP facilities and a specialized biotechnology research institute. Both parties have rich technical expertise and product development experience, along with a strong reputation and influence in the biopharmaceutical field in China.
Through this collaboration, GRIT will leverage its extensive experience in T cell therapy to expedite the advancement and commercialization of cell therapy products, providing a broader range of options and instilling hope for a greater number of solid tumor patients in the Chinese market. Both parties affirm that through their joint efforts, there is anticipation for a broader spectrum of Chinese patients to soon gain access to advanced and efficacious T-cell treatment options with the affordable local IL-2 product.
SOURCE Grit Biotechnology
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。